IP Library › Granted Patent US 7,566,703
Granted Patent B2
US 7,566,703 · App. 11/255,100 · Granted Jul 28, 2009

Semi-soft C-class immunostimulatory oligonucleotides

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,566,703
App. No.
11/255,100
Granted
Jul 28, 2009
Kind
B2
Abstract

The invention relates to specific C-Class semi-soft CpG immunostimulatory oligonucleotides that are useful for stimulating an immune response. In particular the oligonucleotides are useful for treating allergy, such as allergic rhinitis and asthma, cancer and infectious disease, such as hepatitis B and hepatitis C.

Claims (26)

1. An oligonucleotide comprising 5′ T*C_G*T*C_G*T*C_G*T*T*C_G*G*C*G*C_G*C*G*C*C*G 3′ (SEQ ID NO: 2), wherein * represents a stabilized internucleotide linkage, and_represents phosphodiester or phosphodiester-like internucleotide linkage.

2. The oligonucleotide of claim 1 , wherein the oligonucleotide is 5′T*C_G*T*C_G*T*C_G*T*T*C_G*G*C*G*C_G*C*G*C*C*G 3′ (SEQ ID NO: 2), wherein * represents a stabilized internucleotide linkage, wherein 5′ refers to the free 5′ end of the oligonucleotide and 3 refers to the free 3 end of the oligonucleotide.

3. An oligonucleotide comprising: 5′ TC_GTC_GAG_GATC_GGCGC_GCGCCG3′ (SEQ ID NO:4), wherein the oligonucleotide includes at least 2 stabilized internucleotide linkages and represents phosphodiester or phosphodiester-like internucleotide linkage.

4. The oligonucleotide of claim 3 , wherein the oligonucleotide is 5′T*C_G*T*C_G*A*C_G*A*T*C_G*G*C*G*C_G*C*G*C*C*G 3′ (SEQ ID NO:4), wherein * represents a stabilized internucleotide linkage.

5. An oligonucleotide comprising: TCGTCGACGATCGGCGCGCGCCG (SEQ ID NO:4).

6. An oligonucleotide comprising: T*C_G*T*C_G*T*C, wherein * represents a stabilized internucleotide linkage and_represents phosphodiester or phosphodiester-like internucleotide linkage.

7. The oligonucleotide of claim 6 , wherein the oligonucleotide is 5′T*C_G*T*C_G*T*C_G*T*T*C_G*G*C*G*C_G*C*G*C*C 3′ (SEQ ID NO.: 21), wherein 5′ refers to the free 5′ end of the oligonucleotide and 3′ refers to the free 3′ end of the oligonucleotide.

8. The oligonucleotide of claim 6 , wherein the oligonucleotide is 5′ T*C_G*T*C_G*T*C_G*T*T*C_G*G*C*G*C 3′ (SEQ ID NO.:22), wherein 5′ refers to the free 5′ end of the oligonucleotide and 3′ refers to the free 3′ end of the oligonucleotide.

9. The oligonucleotide of claim 6 , wherein the oligonucleotide is 5′ T*C_G*T*C_G*T*C_G*T*T*C_G*G*C*G*C_G*C*G*C 3′ (SEQ ID NO.:23), wherein 5′ refers to the free 5′ end of the oligonucleotide and 3′ refers to the free 3′ end of the oligonucleotide.

10. An oligonucleotide comprising: 5′ T*C_G*T*T*C_G*G, wherein * represents a stabilized internucleotide linkage and_represents phosphodiester or phosphodiester-like internucleotide linkage, wherein 5′ refers to the free 5′ end of the oligonucleotide.

11. The oligonucleotide of claim 10 , wherein the oligonucleotide is 5′ C_G*T*C_G*T*C_G*T*T*C_G*G*C*G*C_G*C*G*C*C*G 3′ (SEQ ID NO.: 15), wherein 5′ refers to the free 5′ end of the oligonucleotide and 3′ refers to the free 3′ end of the oligonucleotide.

12. The oligonucleotide of claim 10 , wherein the oligonucleotide is 5′ G*T*C_G*T*C_G*T*T*C_G*G*C*G*C_G*C*G*C*C*G 3′ (SEQ ID NO.:16), wherein5′ refers to the free 5′ end of the oligonucleotide and 3′ refers to the free 3′ end of the oligonucleotide.

13. The oligonucleotide of claim 10 , wherein the oligonucleotide is 5′ T*C_G*T*C_G*T*T*C_G*G*C*G*C_G*C*G*C*C*G 3′ (SEQ ID NO.:17), wherein 5′ refers to the free 5′ end of the oligonucleotide and 3′ refers to the free 3′ end of the oligonucleotide.

14. The oligonucleotide of claim 10 , wherein the oligonucleotide is 5′ C_G*T*C_G*T*T*C_G*G*C*G*C_G*C*G*C*C*G 3′ (SEQ 113 NO.:18), wherein 5′ refers to the free 5′ end of the oligonucleotide and 3′ refers to the free 3′ end of the oligonucleotide.

15. The oligonucleotide of claim 10 , wherein the oligonucleotide is 5′ G*T*C_G*T*T*C_G*G*C*G*C_G*C*G*C*C*G 3′ (SEQ ID NO.:19), wherein 5′ refers to the free 5′ end of the oligonucleotide and 3′ refers to the free 3′ end of the oligonucleotide.

16. The oligonucleotide of claim 10 , wherein the oligonucleotide is 5′ T*C_G*T*T*C_G*G*C*G*C_G*C*G*C*C*G 3′ (SEQ ID NO.:20), wherein 5′ refers to the free 5′ end of the oligonucleotide and 3′ refers to the free 3′ end of the oligonucleotide.

17. A pharmaceutical composition comprising an oligonucleotide of any one of claims 3 , 4 or 16 , and a pharmaceutically acceptable carrier.

18. The pharmaceutical composition of claim 17 , further comprising a nebulizer.

19. The pharmaceutical composition of claim 17 , further comprising an inhaler.

20. The pharmaceutical composition of claim 19 , wherein the inhaler is a metered dose inhaler.

21. The pharmaceutical composition of claim 19 , wherein the inhaler is a powder inhaler.

22. The pharmaceutical composition of claim 17 , further comprising a chemotherapeutic agent.

23. The pharmaceutical composition of claim 17 , further comprising an anti-viral agent.

24. The pharmaceutical composition of claim 17 , wherein the pharmaceutically acceptable carrier is formulated for subcutaneous administration.

25. The pharmaceutical composition of claim 17 , wherein the pharmaceutically acceptable carrier is formulated for oral administration.

26. The pharmaceutical composition of claim 17 , wherein the pharmaceutically acceptable carrier is formulated for intranasal administration.